For research use only. Not for therapeutic Use.
Motesanib, also known as AMG-706, is the orally bioavailable multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation. (NCI Thesaurus).
| Catalog Number | I008138 |
| CAS Number | 453562-69-1 (Motesanib); 857876-30-3 (Motesanib diphosphate) |
| Molecular Formula | C22H23N5O |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| InChI | InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28) |
| InChIKey | RAHBGWKEPAQNFF-UHFFFAOYSA-N |
| SMILES | O=C(C1=CC=CN=C1NCC2=CC=NC=C2)NC3=CC4=C(C=C3)C(C)(C)CN4 |
| Reference | </br>1:A case report of motesanib-induced biliary sludge formation causing obstructive cholangitis with acute pancreatitis treated by endoscopic sphincterotomy. Song J, Kim SB, Kim KH, Kim TN, Lee KH.Medicine (Baltimore). 2016 Sep;95(37):e4645. doi: 10.1097/MD.0000000000004645. PMID: 27631212 Free PMC Article</br>2:Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients. Gosselin NH, Mouksassi MS, Lu JF, Hsu CP.Clin Pharmacol Drug Dev. 2015 Nov;4(6):463-72. doi: 10.1002/cpdd.196. Epub 2015 Jul 23. PMID: 27137719 </br>3:Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells. Kaya TT, Altun A, Turgut NH, Ataseven H, Koyluoglu G.Asian Pac J Cancer Prev. 2016;17(3):1103-10. PMID: 27039732 Free Article</br>4:Correction: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PLOS ONE Staff..PLoS One. 2015 Mar 26;10(3):e0121162. doi: 10.1371/journal.pone.0121162. eCollection 2015. PMID: 25811784 Free PMC Article</br>5:Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D.Cancer Chemother Pharmacol. 2015 May;75(5):993-1004. doi: 10.1007/s00280-015-2694-y. Epub 2015 Mar 15. PMID: 25772756 </br>6:A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS.Oncotarget. 2014 Nov 30;5(22):11154-67. PMID: 25525888 Free PMC Article</br>7:Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. Bass MB, Yao B, Hei YJ, Ye Y, Davis GJ, Davis MT, Kaesdorf BA, Chan SS, Patterson SD.PLoS One. 2014 Oct 14;9(10):e108048. doi: 10.1371/journal.pone.0108048. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0121162. PMID: 25314641 Free PMC Article</br>8:Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice. Rho CR, Kang S, Park KC, Yang KJ, Choi H, Cho WK.J Ocul Pharmacol Ther. 2015 Feb;31(1):25-31. doi: 10.1089/jop.2014.0023. PMID: 25255037 Free PMC Article</br>9:Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib. Ebadi A, Razzaghi-Asl N, Shahabipour S, Miri R.Iran J Pharm Res. 2014 Spring;13(2):405-15. PMID: 25237336 Free PMC Article</br>10:Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR.J Thorac Oncol. 2014 Aug;9(8):1154-61. doi: 10.1097/JTO.0000000000000227. PMID: 25157768 Free Article |
